Provectus Biopharmaceuticals Secures U.S. Patent for Novel Light-Independent Eye Drop Targeting Drug-Resistant Ocular Infections
PVCT sits 76% above its 52-week low of $0.038.
Summary
Provectus Biopharmaceuticals and its subsidiary VisiRose secured a U.S. patent for a novel light-independent eye drop designed to treat drug-resistant ocular infections like MRSA. This patent is significant as it covers a formulation that kills bacteria and eradicates biofilms without requiring light activation, enabling a standard, self-administered eye drop. For a company facing critical cash shortages and a going concern warning, this intellectual property win provides a crucial positive development, validating its platform and offering a pathway to address a substantial unmet medical need.
At the time of this announcement, PVCT was trading at $0.07 on OTC in the Life Sciences sector, with a market capitalization of approximately $28.2M. The 52-week trading range was $0.04 to $0.11. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.